Release date: 21 March 2007
Promoter – Financial Intermediary
B. Braun Melsungen AGLocation
Description
Construction of a new central laboratory, a pilot plant for production of active pharmaceutical ingredients and the facilities in which the first commercial production will take place, as well as the related RDI activities.
Objectives
The project will enable the promoter to undertake all parts of the pharmaceutical development process, from preclinical to clinical development, in-house.
Comments
Manufacturing
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 150 million.
Total cost (Approximate amount)
EUR 350 million.
Environmental aspects
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. an EIA therefore is not required by EU Directive 97/11. The pilot plant construction and the expansion of the production facilities fall under annex II of the directive EC/97/11. Whether an EIA has been requested by the competent authorities or not, and environmental studies conducted will be verified during project appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
Status
Signed - 7/07/2008
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).